SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
The company reported positive preliminary topline data from its Phase 2 study showing rademikibart significantly reduced COPD exacerbations and hospitalizations, potentially settin…
FactSet Research Systems Inc. filed an exhibit restating its by-laws including amendments as of September 2018 through 2026.
The company filed an exhibit containing forward-looking statements regarding the clinical development, estimated capital requirements, and regulatory activities for its product can…
DBV Technologies submitted a Biologics License Application to the FDA for the peanut patch in children aged 4-7, supported by Phase 3 data. This regulatory milestone marks progress…
Federal banking regulators have published their response letters regarding resolution plans submitted by 15 banking organizations.
IB Acquisition Corp. filed a current report with the SEC, but the specific details about the filing's content are not provided in the disclosed documents.
Tectonic reported favorable safety and tolerability results for its candidate TX2100 at the APJ receptor, triggering its Fast Track designation and allowing progression into Phase …
Turner, Stone & Company审计师致函SEC，确认公司2026年8-K报告中关于其事务所的声明，对不相关部分无异议。
The company confirms minimal exposure to a new Brazilian law banning online betting, with Brazil representing an immaterial share of revenue; legal counsel is reviewing the regulat…
The company received a notification from Nasdaq notifying it of continued non-compliance due to late filings of 10-K and 10-Q forms, maintaining a deadline of Oct. 19, 2026, to pro…
Oncolytics Biotech Inc. announced data demonstrating that its investigational candidate pelareorep transforms immunologically inactive liver tumors into a 'hot' phenotype susceptib…
Greenland Energy Company refuted an analyst report calling it uninvestable, clarifying its financial status and addressing misleading claims about the company's cash position.
Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule after its stock price rose above $1.00 per share for 13 consecutive trading days. The bio…
uniQre N.V. presented an update on the Phase I/II trial of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, continuing to share long-term patient data and evaluation …
Moleculin Biotech announced it has finalized enrollment in the Part A of its Phase 2/3 MIRACLE trial for Annamycin. This achievement positions the company to report pivotal efficac…
Global Business Travel Group, Inc. has filed an exhibit containing its Amended and Restated Certificate of Incorporation, effective immediately.
CareCloud reported that an unauthorized filing of its proxy statement occurred on the SEC website, raising questions about the integrity and current status of the material.
Unicycive resubmitted its oxylanthanum carbonate NDA to the FDA with CMC data from a compliant new vendor, anticipating an FDA acceptance within 30 days and a new PDUFA target date…
The company reported Phase 3 topline results showing VYD2311 demonstrated safety and tolerability clinically superior to mRNA vaccines. This milestone supports the planned Biologic…
The company provided a regulatory update regarding reproxalap and plans for potential clinical trials. It also discussed a formal dispute resolution request with the FDA, highlight…